3 news items
Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
MREO
3 Apr 24
. Under the terms of the agreement, ReproNovo, a reproductive medicine company, is responsible for all future development and commercialization
Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
MREO
27 Mar 24
of leflutrozole, a non-steroidal aromatase inhibitor. Under the terms of the License Agreement, ReproNovo, a reproductive medicine company, is responsible
Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Biopharma Conference
MREO
5 Mar 24
medicine company, is responsible for all future development and commercialization of leflutrozole. For more information
- Prev
- 1
- Next